ARA 290
Also known as Cibinetide. A synthetic peptide engineered from erythropoietin — the hormone your kidneys produce to protect tissue under stress. ARA 290 keeps the tissue-protective signal from EPO while completely removing its red blood cell effects, making it safe for ongoing therapeutic use.
It works by activating a receptor found only in stressed or damaged tissue — one that triggers the body's own repair and anti-inflammatory programs exactly where they're needed. Multiple Phase II clinical trials have documented nerve regeneration, pain reduction, and improved metabolic markers in human patients.
How ARA 290 Works
Your kidneys produce a hormone called erythropoietin — EPO — when the body is under stress. Most people know EPO for its role in producing red blood cells, which is why athletes have misused it. But EPO actually does two completely separate things through two completely separate receptors. One drives red blood cell production in bone marrow. The other — discovered only in the last two decades — activates repair and protection programs in damaged tissue throughout the body.
Researchers Michael Brines and Anthony Cerami at The Feinstein Institute made a key discovery: these two functions could be separated. By engineering a small 11-amino acid fragment of EPO's structure — the part responsible for the tissue-protective signal only — they created ARA 290. It activates what they named the innate repair receptor (IRR) without touching the erythropoiesis pathway at all. No increase in red blood cells. No cardiovascular risk. Just the repair signal.
The innate repair receptor has a critical property: it is largely absent in healthy, uninjured tissue and becomes strongly expressed only in tissue that is damaged, inflamed, or under metabolic stress. This means ARA 290 acts like a precision signal — it goes where the problem is. Once it binds, it activates a cascade that suppresses inflammatory cytokines, prevents cell death, promotes nerve fiber regeneration, and supports tissue repair at the cellular level.
What does "11 amino acids" mean? Amino acids are the building blocks of all proteins and peptides. A full EPO molecule contains 165 amino acids — too large and too indiscriminate to use therapeutically at scale. ARA 290 is just 11 amino acids — a precise fragment engineered to carry only the tissue-protective signal. Think of it as the active key cut from a much larger key ring, shaped to fit only the lock you want to open.
What ARA 290 Does
ARA 290's effects span several systems — all connected by the same underlying mechanism: activating the body's innate repair receptor in tissue that needs it. The clinical trial evidence is strongest for nerve repair and pain reduction. The metabolic and tissue-protective effects are well-supported by both clinical and preclinical research.
This is ARA 290's most clinically documented benefit. Small fiber nerves — the thin sensory nerves responsible for pain perception, temperature detection, and autonomic control — are notoriously difficult to regenerate once damaged. In two separate Phase II randomized controlled trials, ARA 290 produced measurable increases in corneal nerve fiber density (a direct measure of small nerve regrowth) after just 28 days of treatment. These are real structural changes to nerve tissue, not just symptomatic relief.
Neuropathic pain — the burning, tingling, electric-shock sensations caused by damaged nerves — is one of the hardest types of pain to treat. Standard medications like gabapentin and duloxetine blunt the pain signal but do nothing for the underlying nerve damage. ARA 290 works differently: by actually regenerating nerve fibers and reducing the inflammatory environment driving the pain, it addresses the root cause. Clinical trials showed significant reductions in pain scores alongside measurable nerve regrowth.
ARA 290 suppresses the key inflammatory messengers — cytokines like TNF-alpha, IL-1, and IL-6 — that drive chronic tissue inflammation. Crucially, it does this through immunomodulation rather than immunosuppression. It calms overactive inflammatory responses without disabling the immune system's ability to fight infection. This makes it fundamentally different from steroids or immunosuppressants, which broadly shut down immune activity and carry significant long-term risks.
A clinical study in patients with type 2 diabetes found that 28 days of daily ARA 290 improved hemoglobin A1c (a measure of long-term blood sugar control), improved lipid profiles, and produced measurable gains in corneal nerve fiber density — suggesting ARA 290 may slow or partially reverse the nerve damage that accumulates with chronic high blood sugar. The metabolic improvements went beyond what would be expected from nerve protection alone, pointing to a broader role in glucose metabolism and insulin sensitivity.
The innate repair receptor is present across many organ systems — kidneys, heart, lungs, intestinal tissue — and becomes upregulated whenever those tissues are under oxidative or inflammatory stress. Preclinical studies have shown ARA 290 protects kidney tissue from chemotherapy-related damage, reduces cardiac inflammation, and may support recovery from ischemic injury (when blood supply to tissue is temporarily cut off). These findings are preclinical but mechanistically consistent with what has been demonstrated in human nerve tissue.
ARA 290 supports the health of the small blood vessels — the microvascular system — that supply nutrients to nerves, organs, and tissues. Endothelial cells (the cells lining blood vessels) express the innate repair receptor and respond to ARA 290 by improving barrier function and reducing inflammatory signaling. This makes ARA 290 particularly relevant for conditions where microvascular damage is a contributing factor — including diabetic complications, peripheral neuropathy, and age-related tissue deterioration.
The Research Behind ARA 290
ARA 290 has a more substantial clinical evidence base than most peptides available through compounding. Below are the key studies in plain language — what was done, who was studied, and what was found.
Where does the evidence stand? ARA 290 has completed multiple Phase II randomized controlled trials with positive results — a level of clinical evidence that most peptides available through compounding have not reached. It does not yet have Phase III data or FDA approval as a finished product. Its FDA Orphan Drug designation for neuropathic pain in sarcoidosis reflects the strength of existing evidence and the medical need it addresses. As with all compounded peptides, use is under provider supervision and subject to ongoing clinical evaluation.
Common Questions
Side Effects to Watch For
- /Mild redness or irritation at the injection site — rotate sites every injection
- /Temporary fatigue or lightheadedness after infusion — brief, self-resolving
- /Headache or flushing — uncommon, typically mild
- /Mild nausea or flu-like sensations after initial doses — rare, improves with continued use
These symptoms are typically brief and improve as the body adjusts. Contact your provider if anything feels significant or does not resolve on its own.
Learn More About ARA 290
USA-formulated, lab-verified liquid formula. Ready to use — no mixing required. Protocol guidance provided during your consultation.
Learn MoreFor educational purposes only. Many compounds referenced on this site are investigational and not FDA-approved.
Always consult a qualified healthcare provider before starting any peptide regimen.
© 2026 Bespoke Biology